Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 19/20 | 0.46 |
| ▸ | CCND1 | P24385 | 14/20 | 0.46 |
| ▸ | CCND3 | P30281 | 9/20 | 0.43 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643141 | 0.90 | CDK4 (0.47) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL30643103 | 0.88 | CDK4 (0.44) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643116 | 0.88 | CDK4 (0.44) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643138 | 0.88 | CDK4 (0.42) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643125 | 0.86 | CDK4 (0.41) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643140 | 0.82 | CDK4 (0.42) | CDK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL29750280 | 0.82 | CDK4 (0.68) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643100 | 0.82 | CDK4 (0.42) | CDK4CCND1CCND3CDK6 | |
| SCHEMBL30643118 | 0.81 | CDK4 (0.42) | CDK1CDK2CDK4CCND1CCND3 | |
| SCHEMBL30643147 | 0.81 | CDK4 (0.40) | CDK1CDK2CDK4CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519267-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-03-12 | — | — | EP | disclosed |
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-02-27 | — | — | US | disclosed |
| CN-119156389-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | disclosed |
| WO-2023213271-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066372-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CDK1, CDK2, CDK4 | CDK1 1/4885CDK2 2/4885CDK4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.